FDA approves our new treatment for classic congenital adrenal hyperplasia (CAH)
Corporate Sustainability
Click below for our approach to environment, social, and governance (ESG) programs.
Neurocrine Biosciences 2024 Corporate Sustainability Report
Neurocrine Biosciences 2023 Corporate Sustainability Report
To stay up to date on Neurocrine Biosciences, please sign up for our email alerts.
